Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dosimetric Planning Study Comparing Intensity Modulated Radiotherapy (IMRT) and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix

This study has been completed.
Information provided by:
Sunnybrook Health Sciences Centre Identifier:
First received: September 21, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
A theoretical planning study to compare the normal tissue irradiation when using intensity modulated radiotherapy (IMRT) as opposed to standard radiotherapy for the definitive treatment of cervical cancer.

Condition Intervention Phase
Cervix Cancer
Radiation: IMRT planning
Radiation: 4-Field Radiation Planning
Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dosimetric Planning Study Comparing IMRT and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix

Resource links provided by NLM:

Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • Reduction in dose to organs at risk [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Target Coverage [ Time Frame: 6 months ]

Enrollment: 55
Study Start Date: December 2008
Study Completion Date: September 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Cervix Cancer
Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
Radiation: IMRT planning Radiation: 4-Field Radiation Planning

Detailed Description:
Radiotherapy in combination with chemotherapy is the standard treatment of locally advanced cervix cancer, however with traditional techniques large volumes of bowel and bladder are irradiated causing short-term and long-term genito-urinary and gastro-intestinal side effects. IMRT has the potential to conform precisely to the target and spare normal tissues and reduce side effects. However because there are large dose gradients there is the potential to miss the target due to organ motion. Recent studies have documented organ motion and will be used to define the target. Approximately 60 planning scans, previously used to treat patients with cervix cancer, will be used to replan using an IMRT technique and differences in doses to tumour and normal tissues compared.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • last 60 patients treated definitively for cervical cancer at Sunnybrook Odette Cancer Centre

Exclusion Criteria:

  • no imaging and no anatomical description of disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00981552

Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Principal Investigator: Gillian Thomas, MD Sunnybrook Health Sciences Centre
  More Information

Responsible Party: Dr Gillian Thomas, Sunnybrook Health Sciences Centre Identifier: NCT00981552     History of Changes
Other Study ID Numbers: IMRTCC
Study First Received: September 21, 2009
Last Updated: September 21, 2009

Keywords provided by Sunnybrook Health Sciences Centre:
Cervix Cancer
Organ Motion
Target Definition

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female processed this record on April 28, 2017